NASDAQ:CRNXCrinetics Pharmaceuticals Stock Price, Forecast & News

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRNX shares have increased by 5.6% and is now trading at $16.37. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its earnings results on Friday, May, 8th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.08. The business had revenue of $0.07 million for the quarter. View Crinetics Pharmaceuticals' earnings history.

3 analysts have issued twelve-month target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $38.00. On average, they anticipate Crinetics Pharmaceuticals' share price to reach $35.00 in the next twelve months. This suggests a possible upside of 113.8% from the stock's current price. View analysts' price targets for Crinetics Pharmaceuticals.

Media headlines about CRNX stock have trended somewhat negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of -1.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutCrinetics Pharmaceuticals.

Some companies that are related to Crinetics Pharmaceuticals include Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), SAGE Therapeutics (SAGE), IGM Biosciences (IGMS), Epizyme (EPZM), Pacira Biosciences (PCRX), Madrigal Pharmaceuticals (MDGL), Xencor (XNCR), Eidos Therapeutics (EIDX), Aurinia Pharmaceuticals (AUPH) and Zymeworks (ZYME). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Arbutus Biopharma (ABUS), Axsome Therapeutics (AXSM), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Immunomedics (IMMU), SCYNEXIS (SCYX), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD) and Apellis Pharmaceuticals (APLS).

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vivo Capital LLC (10.11%), RA Capital Management L.P. (5.97%), 5AM Venture Management LLC (7.58%), BlackRock Inc. (2.94%), Janus Henderson Group PLC (1.50%) and Burrage Capital Management LLC (0.86%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View institutional ownership trends for Crinetics Pharmaceuticals.

CRNX stock was sold by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Morgan Stanley, Victory Capital Management Inc., Victory Capital Management Inc., BlackRock Inc., UBS Group AG, Alps Advisors Inc., and Hershey Trust Co.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Ventures Iv LP 5Am, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

CRNX stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, RA Capital Management L.P., Burrage Capital Management LLC, Geode Capital Management LLC, Alliancebernstein L.P., Janus Henderson Group PLC, BNP Paribas Arbitrage SA, and Citigroup Inc.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive, and Vivo Capital Viii, Llc. View insider buying and selling activity for Crinetics Pharmaceuticals.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRNX stock can currently be purchased for approximately $16.37.

Crinetics Pharmaceuticals has a market capitalization of $537.69 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]